Search results for "Acellular"

showing 10 items of 1986 documents

Non-local multiscale approach for the impact of go or grow hypothesis on tumour-viruses interactions

2021

International audience; We propose and study computationally a novel non-local multiscale moving boundary mathematical model for tumour and oncolytic virus (OV) interactions when we consider the go or grow hypothesis for cancer dynamics. This spatio-temporal model focuses on two cancer cell phenotypes that can be infected with the OV or remain uninfected, and which can either move in response to the extracellular-matrix (ECM) density or proliferate. The interactions between cancer cells, those among cancer cells and ECM, and those among cells and OV occur at the macroscale. At the micro-scale, we focus on the interactions between cells and matrix degrading enzymes (MDEs) that impact the mov…

Non-local cell adhesion[SDV]Life Sciences [q-bio]Multiscale cancer modellingBiologyMatrix (biology)Models BiologicalVirusMigration-proliferation dichotomyExtracellular matrix03 medical and health sciences0302 clinical medicineNeoplasmsmedicineQA1-939HumansNeoplasm Invasiveness[NLIN]Nonlinear Sciences [physics][MATH]Mathematics [math]030304 developmental biology0303 health sciencesApplied MathematicsCancerGo or grow hypothesisGeneral Medicinemedicine.diseasePhenotypeExtracellular MatrixCell biologyOncolytic virusOncolytic VirusesComputational MathematicsViral replication030220 oncology & carcinogenesisModeling and SimulationTumour-oncolytic viruses interactionsCancer cellOncogenic VirusesGeneral Agricultural and Biological SciencesTP248.13-248.65MathematicsBiotechnology
researchProduct

Freeze-fracture features of epithelioid cells, multinucleated giant cells, and phagocytic macrophages

1987

The freeze-fracture morphology of epithelioid cells, multinucleated giant cells (Langhans' type), and phagocytic macrophages was investigated. The intensely folded and interdigitating surface membranes of epithelioid cells and multinucleated giant cells displayed no specialized areas of cell contact. The size of the intramembranous particles (IMP) and the fact that the area density of IMPs was higher in the cytoplasmic (P) faces than in the external (E) faces of the cell membranes agreed with observations in other eukaryotic cells. The area densities of the IMPs suggest lower transport rates of molecules across the cell membranes of granuloma cells than of certain epithelial cells. Small pi…

Nuclear EnvelopeLanghans giant cellBiologyEpitheliumCell membranemedicineAnimalsFreeze FracturingCell NucleusPhagocytesGranulomaNucleoplasmMacrophagesCell MembraneGranule (cell biology)Membrane ProteinsIntracellular MembranesRatsCell biologyCell nucleusmedicine.anatomical_structureGiant cellCytoplasmNephritis InterstitialLysosomesEpithelioid cellVirchows Archiv B Cell Pathology Including Molecular Pathology
researchProduct

COMPOSITION AND EFFECTS OF EXTRACELLULAR VESICLES SHED BY OLIGODENDROGLIOMA CELLS

2011

OLIGODENDROGLIOMA CELLSSettore BIO/10 - BiochimicaEXTRACELLULAR VESICLES
researchProduct

Optimization of a decellularized protocol of porcine tracheas. Long-term effects of cryopreservation. A histological study

2021

[EN] Objective: The aim of this study was to optimize a decellularization protocol in the trachea of Sus scrofa domestica (pig) as well as to study the effects of long-term cryopreservation on the extracellular matrix of decellularized tracheas. Methods: Porcine tracheas were decellularized using Triton X-100, SDC, and SDS alone or in combination. The effect of these detergents on the extracellular matrix characteristics of decellularized porcine tracheas was evaluated at the histological, biomechanical, and biocompatibility level. Morphometric approaches were used to estimate the effect of detergents on the collagen and elastic fibers content as well as on the removal of chondrocytes from …

OctoxynolSwine0206 medical engineeringTracheal stenosisBiomedical EngineeringMedicine (miscellaneous)Bioengineering02 engineering and technologyCryopreservationBiomaterialsAndrology03 medical and health sciences0302 clinical medicineMedicineSDSCryopreservationDecellularizationTissue EngineeringTissue Scaffoldsbusiness.industryTracheal histologyDecellularized tracheasAirway tissue engineeringGeneral Medicine020601 biomedical engineeringTracheal StenosisSus scrofa domesticaExtracellular MatrixTrachea030220 oncology & carcinogenesisFISICA APLICADAbusiness
researchProduct

Microvesicles shed by oligodendroglioma cells and rheumatoid synovial fibroblasts contain aggrecanase activity

2012

Membrane microvesicle shedding is an active process and occurs in viable cells with no signs of apoptosis or necrosis. We report here that microvesicles shed by oligodendroglioma cells contain an ‘aggrecanase’ activity, cleaving aggrecan at sites previously identified as targets for adamalysin metalloproteinases with disintegrin and thrombospondin domains (ADAMTSs). Degradation was inhibited by EDTA, the metalloproteinase inhibitor GM6001 and by tissue inhibitor of metalloproteinases (TIMP)-3, but not by TIMP-1 or TIMP-2. This inhibitor profile indicates that the shed microvesicles contain aggrecanolytic ADAMTS(s) or related TIMP-3-sensitive metalloproteinase(s). The oligodendroglioma cells…

OligodendrogliomaMembrane vesicleRA rheumatoid arthritisADAMTSMatrix metalloproteinaseCell Physiological PhenomenaAdamalysin03 medical and health sciences0302 clinical medicineSettore BIO/10 - BiochimicaEndopeptidasesHumansAggrecansADAM adamalysinADAMTS a disintegrin and metalloproteinase with thrombospondin motifsMolecular BiologyMetalloproteinase030304 developmental biologyAggrecanaseTissue Inhibitor of Metalloproteinase-3MEF mouse embryonic fibroblasts0303 health sciencesMetalloproteinaseChemistryBrief ReportMVs microvesiclesADAMTSMicrovesicleCytoplasmic VesiclesDipeptidesFibroblastsMolecular biologyRecombinant ProteinsMicrovesiclesECM extracellular matrixMembrane vesiclesCell biologyEnzyme ActivationMMP matrix metalloproteinaseADAM ProteinsADAMTS4030220 oncology & carcinogenesisProteolysisADAMTS5 ProteinRheumatic FeverTIMP tissue inhibitor of metalloproteinaseAggrecan
researchProduct

(2'-5')Oligoadenylate and intracellular immunity against retrovirus infection.

1992

1. 1. The double-stranded RNA-dependent 2′,5′-oligoadenylate (2–5A) synthetase/ribonuclease L (RNase L) system plays an essential role in the establishment of the antiviral state of a cell exposed to virus infection. 2. 2. Until recently, the application of 2–5A derivatives to reinforce this system seemed to be limited mainly due to the low specificity of RNase L for viral RNA. 3. 3. Two new strategies have been developed which yield a selective antiviral effect of 2–5As at least against human immunodeficiency virus-1 (HIV-1) infection: (i) an “intracellular immunization” appproach using 2-5A synthetase cDNA linked to HIV trans -acting response element (TAR) and (ii) inhibition of retrovira…

OligoribonucleotidesbiologyRNase P2'-5'-OligoadenylateAdenine NucleotidesHIVbiology.organism_classificationVirus ReplicationBiochemistryVirologyMolecular biologyAntiviral AgentsVirusRetrovirusBiochemistryImmunityComplementary DNAbiology.protein2'5'-Oligoadenylate SynthetaseReverse Transcriptase InhibitorsRibonuclease LIntracellularHIV Long Terminal RepeatRetroviridae InfectionsThe International journal of biochemistry
researchProduct

Tissue factor and its procoagulant activity on cancer‐associated thromboembolism in pancreatic cancer

2021

Abstract Pancreatic cancer frequently involves cancer‐associated thromboembolism, which is strongly associated with poor prognosis. Tissue factor, a blood coagulation factor largely produced in cancer patients as a component of extracellular vesicles, plays a key role in the incidence of cancer‐associated thromboembolism in patients with pancreatic cancer. However, no prospective studies have been published on the relationship between tissue factor and cancer‐associated thromboembolism or patient clinical characteristics, including recent chemotherapy regimens. Thus, we aimed to address this in a Japanese cohort of 197 patients and 41 healthy volunteers. Plasma tissue factor levels were mea…

OncologyAdultMaleRiskCancer Researchmedicine.medical_specialtyEnzyme-Linked Immunosorbent AssayThromboplastinCohort StudiesTissue factorExtracellular VesiclesJapanClinical ResearchPredictive Value of TestsPancreatic cancerInternal medicineThromboembolismmedicineConfidence IntervalsHumansRisk factorProspective cohort studyAgedAged 80 and overbusiness.industryCancerpancreatic neoplasmGeneral MedicineExtracellular vesicleOriginal ArticlesVenous ThromboembolismMiddle Agedmedicine.diseasetissue factorPancreatic NeoplasmsOncologyrisk factorRelative riskCase-Control StudiesCohortMultivariate AnalysisOriginal ArticleFemaleextracellular vesiclebusinessCancer Science
researchProduct

A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing live…

2010

Abstract Background The potential anti-cancer effects of mammalian target of rapamycin (mTOR) inhibitors are being intensively studied. To date, however, few randomised clinical trials (RCT) have been performed to demonstrate anti-neoplastic effects in the pure oncology setting, and at present, no oncology endpoint-directed RCT has been reported in the high-malignancy risk population of immunosuppressed transplant recipients. Interestingly, since mTOR inhibitors have both immunosuppressive and anti-cancer effects, they have the potential to simultaneously protect against immunologic graft loss and tumour development. Therefore, we designed a prospective RCT to determine if the mTOR inhibito…

OncologyCancer ResearchTime Factorsmedicine.medical_treatmentMedizinIntracellular Signaling Peptides and Proteins - antagonists & inhibitors metabolismKaplan-Meier Estimate312 Clinical medicineProtein-Serine-Threonine KinaseLiver transplantationTHERAPYStudy ProtocolImmunosuppressive Agentendothelial growth-factor renal-cell carcinoma tumor progression rapamycin cancer cyclosporine efficacy therapy target model0302 clinical medicineRENAL-CELL CARCINOMARisk FactorsRecurrenceSurgical oncologyMedicine and Health SciencesLiver Neoplasms - drug therapy enzymology mortality surgerySirolimuProspective StudiesTUMOR PROGRESSIONTransplantation Homologoueducation.field_of_studyliver transplantationTOR Serine-Threonine KinasesLiver NeoplasmsIntracellular Signaling Peptides and ProteinsImmunosuppressionhepatocellular carcinomalcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCANCER3. Good healthEuropeMulticenter StudyTreatment OutcomeTARGETsirolimusOncologyLiver Neoplasm030220 oncology & carcinogenesisHepatocellular carcinomaRandomized Controlled TrialmTORCarcinoma Hepatocellular - drug therapy enzymology mortality surgery030211 gastroenterology & hepatologyImmunosuppressive AgentsRCTHumanmedicine.drugCanadamedicine.medical_specialtyCarcinoma HepatocellularTime FactoreducationPopulationLiver Transplantation - adverse effects mortalityProtein Serine-Threonine Kinaseslcsh:RC254-282Disease-Free Survival03 medical and health sciencesInternal medicineGeneticsmedicineTransplantation HomologousHumansComparative StudyRapamycinddc:610educationProtein-Serine-Threonine Kinases - antagonists & inhibitors metabolismKaplan-Meiers Estimatebusiness.industryRisk FactorAustraliaImmunosuppressive Agents - therapeutic useSirolimus - therapeutic useEFFICACYHumans; Liver Transplantation; Hepatocellular Carcinoma; Randomized Controlled Trial; RCT; Multicenter Study; Comparative Study; Rapamycin; mTOR; Sirolimusmedicine.diseaseSurgeryMODELTransplantationClinical trialProspective StudieIntracellular Signaling Peptides and ProteinSirolimusENDOTHELIAL GROWTH-FACTORCYCLOSPORINERAPAMYCINbusiness
researchProduct

1308 Evaluating the prognostic role of serum extracellular domain (ECD) of HER-2/neu (s-HER2) in patients (PTS) with metastatic (M) breast cancer (BC…

2009

OncologyCancer Researchmedicine.medical_specialtybusiness.industrymedicine.diseaseDomain (software engineering)Breast cancerOncologyHer 2 neuInternal medicineExtracellularMedicineObservational studyIn patientbusinessEuropean Journal of Cancer Supplements
researchProduct

Intracellular signalling via the AKT axis and downstream effectors is active and prognostically significant in cancer of unknown primary (CUP): a stu…

2012

Background: Hypothesising that cancer of unknown primary (CUP) may harbour unique characteristics, we present a translational study of the immunohistochemical expression and clinical correlation of key PTEN/AKT pathway molecules. Patients and methods: We collected 100 paraffin-embedded CUP tissue blocks. We studied using tissue microarrays the expression of PTEN, phospho-AKT, Cyclin D1, p21, phospho-RPS6. From the percentage of staining tumour cells and the literature, we selected cut-offs to classify the expression of each biomolecule. We correlated IHC expression with clinical data. Results: PTEN, pAKT, and pRPS6 showed frequent expression. At univariate analysis, high IHC expression of p…

OncologyMalePathologyP21Signal transductionMitogen activated protein kinaseTissue microarrayCancer riskNeoplasmsSquamous cell carcinomaCarcinomatous peritonitisCancer of unknown primary (cup)MedicineOverall survivalPriority journalSurvival timeUnivariate analysisTissue microarraybiologyUnknown primaryHematologyClassificationPrognosisImmunohistochemistryPtenRetrospective studyOncologyIntracellular signalingImmunohistochemistryFemaleCyclin d1Cancer tissueProtein p21HumanSignal Transductionmedicine.medical_specialtyTranslational studyMajor clinical studyCancer mortalityAdenocarcinomaArticleCyclin D1Disease associationInternal medicineTissue array analysisPTENHumansHuman tissueProtein kinase BPI3K/AKT/mTOR pathwayCancer prognosisSurvival predictionDigestive system cancerbusiness.industryAkt/PKB signaling pathwayAktCancer of unknown primary siteProto-oncogene proteins c-aktRps6Protein kinase bTissue Array Analysisbiology.proteinProtein expressionProgression free survivalProtein s6Neoplasms Unknown PrimarybusinessTissue preparationProto-Oncogene Proteins c-aktAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct